Results 151 to 160 of about 34,322 (240)

Acne treated with tumor necrosis factor inhibitors. [PDF]

JAAD Int
Bizuneh LG, Coates SJ, Naik HB, Mathes E, Amerson E.   +4 more
europepmc   +1 more source

Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching

Pediatric Dermatology, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to ...
Shaliz Aflatooni, Andrea Ure, Kimberly Smart, Julian A. Cortes, Gabriela Palma, Nicole Johnsen, Yvonne Nong, April W. Armstrong   +7 more
wiley   +1 more source

Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. [PDF]

Medicina (Kaunas)
Indrisiunaite E, Jonaityte IR, Karmaziene T, Raudonis T.   +3 more
europepmc   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center. [PDF]

Ther Adv Musculoskelet Dis
Agrawal A, Yadav SS, Balakrishnan C.
europepmc   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Case Report: Successful treatment of SAPHO syndrome refractory to adalimumab with upadacitinib. [PDF]

Front Immunol
Du J, Li Y, Geng S, Li C, Shang S.
europepmc   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis. [PDF]

Pediatr Rheumatol Online J
Carrim M, Shipa MRA, Bouraoui A, AlSulaim T, Fisher C, Glanville JRW, Leandro M, Sen D.   +7 more
europepmc   +1 more source

Frailty Rather Than Age Increases the Risk of Infections in Patients With Inflammatory Bowel Disease Treated With Biologics: An Observational Retrospective Cohort Study

JCC Plus, Volume 1, Issue 5, September 2026.
Frailty, rather than age alone, independently predicted infections in IBD patients receiving biologic therapy, with higher risks of both overall and severe infections. Routine frailty assessment may improve infection risk stratification and support more tailored management before and during treatment with biologics.
Elisa Fuochi, Tommaso Innocenti, Saverio Caini, Erica N. Lynch, Armando Curto, Giuseppe Macrì, Francesca Rogai, Stefano Milani, Andrea Galli, Gabriele Dragoni, Siro Bagnoli   +10 more
wiley   +1 more source